19
Participants
Start Date
September 30, 2006
Primary Completion Date
September 30, 2008
Study Completion Date
September 30, 2008
Pemetrexed - Before Protocol Amendment
500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
Pemetrexed - After Protocol Amendment
500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milan
Eli Lilly and Company
INDUSTRY